(E)-5-methoxy-3-((3-((E)-2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)methylene)indolin-2-one | 1168721-94-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: (E)-5-methoxy-3-((3-((E)-2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)methylene)indolin-2-one
• 英文别名: (3E)-5-methoxy-3-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]methylidene]-1H-indol-2-one
• CAS: 1168721-94-5
• 化学式: C₂₄H₁₈N₄O₂
• 分子量: 394.433
• InChiKey: RSCYVMODCXZPDC-XCHVBMRISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  79.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-5-methoxy-3-((3-((E)-2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)methylene)indolin-2-one 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以35%的产率得到2-((E)-2-(6-((E)-(5-methoxy-2-oxoindolin-3-ylidene)methyl)-1H-indazol-3-yl)vinyl)pyridine 1-oxide
  参考文献：
  名称：

  [EN] INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  [FR] DÉRIVÉS D'INDOLMONE À SUBSTITUTION INDAZOLYLE, BENZIMIDAZOLYLE, BENZOTRIAZOLYLE EN TANT QU'INHIBITEURS DE KINASES UTILISÉS DANS LE TRAITEMENT DU CANCER

  摘要：

  公开号：

  WO2009079767A9

文献信息

• INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  申请人：Pauls Heinz W.

  公开号：US20110065702A1

  公开（公告）日：2011-03-17

  The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，其结构式表示为(A)或其药学上可接受的盐。本发明还涉及一种药物组合物，包括上述结构式(A)所表示的化合物或其药学上可接受的盐，以及药学上可接受的载体或稀释剂。本发明还揭示了一种治疗患有癌症的受试者的方法，其中该方法包括给予上述结构式(A)所表示的化合物或其药学上可接受的盐的治疗有效量。
• Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
  申请人：Pauls Heinz W.

  公开号：US08765748B2

  公开（公告）日：2014-07-01

  The present invention is directed to a compound is represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.

  本发明涉及一种由结构式（A）表示的化合物或其药学上可接受的盐。本发明还涉及一种药物组合物，包括上述结构式（A）表示的化合物或其药学上可接受的盐，以及药学上可接受的载体或稀释剂。本发明还揭示了一种治疗癌症患者的方法，其中该方法包括给予上述结构式（A）表示的化合物或其药学上可接受的盐的治疗有效量。
• INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  申请人：University Health Network

  公开号：EP2235004A1

  公开（公告）日：2010-10-06
• METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR
  申请人：Pan Guohua

  公开号：US20130123273A1

  公开（公告）日：2013-05-16

  Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.
• US8765748B2
  申请人：——

  公开号：US8765748B2

  公开（公告）日：2014-07-01